All United States articles

  • White House
    Industry news

    US could ‘seize’ drug patents with unused Reagon-era law

    2023-12-11T16:00:00Z

    The Biden administration sets new policy direction that could see the US federal government ‘seizing’ patents from publicly-funded medicines.

  • AdobeStock_540782876
    Journal

    Controlled substances development – past, present, and future

    2023-11-03T00:05:00Z

    Controlled substances present unique challenges and extra regulations compared to their non-controlled counterparts. Over time in Europe and the US, governing bodies have continually increased the burden on sponsors to demonstrate safety and efficacy. This includes legislation specific to controlled substances; dictating how they can be stored, destroyed, labeled, administered, ...

  • AdobeStock_207448226
    CPD Supplement

    Digital health technologies – an overview of EU and US frameworks

    2021-10-01T10:00:00Z

    Digital health technologies have revolutionised the global healthcare system. This continuing professional development supplement provides an overview of the qualification frameworks for digital health technologies, which are used as drug development tools in the EU and the US.

  • AdobeStock_414656141_Editorial_Use_Only
    Journal

    Eluvia: a drug-eluting stent

    2019-05-01T16:08:00Z

    Peripheral arterial disease (PAD) affects around 8–12 million people in the US.[1] The strong association with ageing, tobacco smoking, and diabetes means that the prevalence of PAD will continue to increase in the coming years. Although 20–50% of patients with PAD are asymptomatic, they are still at significant risk of ...

  • AdobeStock_414656141_Editorial_Use_Only
    Journal

    FDA regulatory pathways for medical devices

    2019-05-01T15:59:00Z

    The regulations, developed as a result of the 1976 Medical Device Amendments to the Food, Drug, and Cosmetic Act of 1938, share a common goal with the pharmaceutical regulations: they both strive to ensure that new medical treatments reach the public as quickly as possible while protecting patients and ensuring that the new treatments have a positive benefit–risk balance. However, they approach this goal in different ways. This continuing professional development supplement explains the fundamentals of the FDA regulatory pathways for medical device manufacturers that wish to bring their products to the US market.